This Pharma Stock with specialization in APIs is in focus as its stock has surged by 17.85 percent following its robust Q4 FY25 results, with Strong growth on its QoQ Net Profit and Revenue
With a market capitalization of Rs. 3,653 Crore, the stock of Aarti Drugs opened at Rs. 357.85, up 2.31 percent from yesterday’s close, and after opening, it made a high of Rs. 412.20, up 17.85 percent. Additionally, the Yearly return for the stock is -16 percent, and the past 5-year return is an impressive 111 percent.
Q4 FY25 Financial Highlights
The company reported a 9.91 percent YoY increase in revenue from Rs. 620 Crore in Q4FY24 to Rs. 677 Crore in Q4FY25. On a QoQ basis, the company reported an increase of 21.54 percent in revenue from Rs. 557 Crore in the previous quarter.
Their Net profit saw an increase of 34.04 percent YoY from Rs. 47 Crore to Rs. 63 Crore for the same period. On a QoQ basis, the company reported an impressive increase of 70.27 percent in Net profit from Rs. 37 Crore in the previous quarter.
The QoQ Net Profit increase of 70.27 percent can be attributed to a 21.54 percent increase in revenue and a smaller increase in cost of material consumed compared to the revenue increase
On a YoY basis, the EBITDA margin didn’t see any change from Q4 FY24 to Q4 FY25 and stayed at 14 percent; however, the PAT Margin increased by 160 bps from 7.60 percent to 9.20 percent for the same period.
About the Company
Headquartered in Mumbai and established in 1984, Aarti Drugs specializes in the manufacture and sale of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations.
The company’s product portfolio includes 50+ API molecules, covering therapeutic areas such as antibiotics, antiprotozoal, anti-inflammatory, anti-diabetic, and antifungal. Notably, Aarti Drugs is the largest global producer of Fluoroquinolones, Tinidazole, Metronidazole Benzoate, Celecoxib, Nimesulide, and Ketoconazole, and ranks among the top manufacturers of Metformin worldwide.
Written By Abhishek Das
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
